BMS finalizes sale of European facility


WuXi STA will take reigns of the operations, as CDMO expands

Bristol Myers Squibb (BMS) has officially completed the previously announced sale of its manufacturing facility in Couvet, Switzerland to WuXi STA, a subsidiary of WuXi AppTec and a contract development and manufacturing organization (CDMO) serving the life sciences industry.

As part of the deal, WuXi STA is acquiring the Couvet site’s operations and assets, which include the plant and equipment, as well as inheriting a technically experienced workforce.

The Couvet site is located in the canton of Neuchâtel, Switzerland. It is a state-of-the-art manufacturing facility with commercial-scale production capacity for capsule and tablet dosage forms.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.